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We used 5 diagnostic tests in a cross-sectional inves-
tigation of the prevalence of Trypanosoma cruzi in Tejupilco
municipality, State of Mexico, Mexico. Our findings showed
a substantial prevalence of immunoglobulin G (IgG) and
IgM antibodies to T. cruzi in human (n = 293, IgG 2.05%,
IgM 5.5%, both 7.1%) and dog (n = 114, IgG 15.8%, IgM
11.4%, both 21%) populations. We also found antibodies to
T. cruzi (n = 80, IgG 10%, IgM 15%, both 17.5%) in dogs
from Toluca, an area previously considered free of T. cruzi.
Our data demonstrate the need for active epidemiologic
surveillance programs in these regions. A direct correlation
(r2 = 0.955) of seropositivity between humans and dogs
suggests that seroanalysis in dogs may help identify the
human prevalence of T. cruzi infection in these areas. 
T
rypanosoma cruzi, which causes Chagas disease,
affects  ≈17.4 million people in the Western
Hemisphere (1). The first case of human infection with T.
cruzi in Mexico was reported in 1936 (2). A national sero-
survey from 1987 to 1989 reported a seroprevalence of
1.6% (»1.6 million people) and widespread T. cruzi infec-
tion in the inhabitants of 23 of the 32 provinces of Mexico
(3,4). A similar prevalence of T. cruzi–specific antibodies
(1.5%) was observed in national blood bank repositories
(5). Rural Mexican villages were confirmed as endemic
zones for T. cruzi. Other investigators reported <20%
seropositivity in inhabitants of rural areas south of the
Tropic of Cancer (4,6,7).
In 1992, the State of Mexico was documented to be free
of T. cruzi (n = 2,800 seropositive, <0.2%) (3). Another
survey of 3,300 blood donors in Mexico City identified a
seropositive rate of 0.3% (8), and many of these donors
had no history of traveling to disease-endemic areas. Other
studies from 1998 to 2000 reported acute cases of T. cruzi
infection and seropositivity among inhabitants of the State
of Mexico (9 and C. Guzman-Bracho, unpub. data).
Circulation of T. cruzi is maintained by the interaction
of bloodsucking triatomines with humans and reservoir
animal hosts (1). Of the 31 triatomine species identified in
Mexico,  Triatoma barberi,  Triatoma dimidiata, and
Triatoma pallidipennis have the highest vectorial activity
in central and southern Mexico (4,10,11). An entomologic
survey in the spring of 2001 documented widespread dis-
tribution of T.  pallidipennis in the southern part of the
State of Mexico (infestation index 9.9%, density index
2.7%–3.0%) and suggested that active transmission of T.
cruzi may occur (12). 
Dogs are considered important in the dynamics of T.
cruzi infection of triatomines and transmission within
human dwellings (1,13,14). Seropositive domestic and
stray dogs have been found in some states of Mexico
(15–17). However, the prevalence of T. cruzi in dogs and
the role of these reservoir animals in parasite transmission
in the State of Mexico have not been determined. 
In this study, we report the seroprevalence of T. cruzi
among persons and dogs in the villages in the southern part
of the State of Mexico and discuss the potential diagnostic
meaning of seropositivity in dogs for identifying sero-
prevalence in humans. We also present data suggesting the
likelihood of T. cruzi transmission in Toluca. Our observa-
tions emphasize that relevant health agencies need to
conduct active epidemiologic surveillance programs and
implement vector control strategies in the State of Mexico.
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Parasites
T. cruzi epimastigotes were cultivated as previously
described (18). Epimastigote (Mexican isolates) antigen
extract was used for the serologic tests conducted at the
Instituto de Diagnostico y Referencia Epidemiologicos
Secretaría de Salud (InDRE) Mexico City. Trypoma-
stigotes (SylvioX10/4) were propagated in monolayers of
C2C12 cells (19) and used in the studies at the University
of Texas Medical Branch (UTMB) in Galveston.
Study Area, Population, and Sample Collection 
This study was conducted in southern villages of the
Tejupilco municipality, State of Mexico (Figure 1). The
area has seasonal climate variations (dry season from
November through May and rainy season from June
through October). The population is primarily indigenous,
and the main occupations are agriculture and livestock pro-
duction. Migration occurs among the men to cities in
Mexico and to northern border regions near the United
States. 
For the human serosurvey (N = 356), we selected 5 vil-
lages (altitude range 1,090–1,730 m) where triatomine
infestation was reported by the Instituto de Salud del Estado
de Mexico (ISEM) in >50% of the households. For compar-
ison, we also selected La Comunidad village (altitude 2,500
m) in the same area. Since this study focused on evaluating
active T. cruzi transmission, most test samples (>94%) were
from children (age range 2–15 years) with a sex distribution
consistent with the regional and national census. Sample
randomization was controlled by using EpiInfo version
3.3.2 (Centers for Disease Control and Prevention, Atlanta,
GA, USA). Oral informed consent was obtained from
adults and parents of minors enrolled in the study. Trained
ISEM personnel performed venipuncture to obtain blood
samples. The study was reviewed and approved by the
human subjects committees at ISEM and UTMB.
Dog serum samples were collected in Toluca and the
villages selected for human screening. Toluca, the capital
of the State of Mexico (altitude 2,680 m, average temper-
ature 15°C, range 5°C–24°C) is considered free of vectori-
al  T. cruzi transmission because triatomines (with or
without T. cruzi) have never been documented in the area,
and triatomines are believed not to proliferate at altitudes
>2,500 m (3,4). Serum samples from 20 healthy dogs from
an animal clinic in Hamburg, Germany, were used as neg-
ative controls. All animal experiments were reviewed and
approved by the animal welfare committee at ISEM. 
Serologic Analysis 
At UTMB, human and dog serum samples were
screened for antibodies to T.  cruzi by enzyme-linked
immunosorbent assay (ELISA) as previously described
(20,21). All samples and controls were assayed in triplicate
in at least 2 independent experiments. Seropositive sam-
ples were confirmed by immunofluorescence flow cytom-
etry (IFC) (21), and data were expressed as the relative
percentage of positively fluorescent parasites. 
At InDRE, serum samples were analyzed for
immunoglobulin G (IgG) antibodies to T. cruzi by ELISA,
an indirect hemagglutination (IHA) test, and an indirect
immunofluorescence (IIF) assay. For the ELISA, 96-well,
flat-bottomed plates were UV irradiated, incubated for 1 h
at 37°C with epimastigote antigen extract, and blocked
with 50 µL Tris-buffered saline, 0.1% Tween 20, and 5%
nonfat dry milk. Plates were incubated at 37°C with 50 µL
of each test serum sample (1:50 dilution) for 2 h, horserad-
ish peroxidase–conjugated IgG (1:50 dilution) for 1 h, and
substrate (o-phenylenediamine) for 20 min. The reaction
was stopped by adding 2 N H2SO4, and the optical density
(OD) was read at 490 nm (22). The IHA and IIF assays
were performed with 4-fold serial dilutions of serum sam-
ples (range 1:8–1:128) (5), and samples were considered
seropositive when a strong signal was obtained at a dilu-
tion >1:16. Epimastigote antigen extract was not used to
determine IgM seropositivity for T. cruzi in this study
because it has shown limited sensitivity (23,24). 
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Figure 1. Study site in Mexico. A) Country of Mexico. B) State of
Mexico. C) Southern part of the State of Mexico. Shown are the
municipalities and villages in the State of Mexico where epidemio-
logic serosurveys were conducted.Statistical Analysis
Significance (p<0.05) was determined with the Student
t test and validated with the Fisher exact test. The level of
agreement for serologic data from 5 tests conducted at
UTMB and InDRE was assessed as previously described
(25).
Results
Standardization of Serologic Assays 
Results of the trypomastigote-based ELISAs for IgG
and IgM antibodies in positive and negative samples are
shown in Figure 2. Variations in reactivity of negative and
positive sera in different experiments and the same exper-
iment ranged from 3% to 12%. The highest signal-to-noise
ratios between positive and negative controls from humans
(IgG 4.0, 6.5, 9.1 and IgM 3.6, 5.5, 11.3) were obtained at
dilutions of 1:80, 1:160, and 1:320, respectively (Figure
2A). Thirty-five serum samples and pooled negative sam-
ples (1:100 dilution) were analyzed by ELISA(Figure 2A).
Mean cutoff OD values were 0.194 for IgG and 0.270 for
IgM.
The highest signal-to-noise ratios by ELISA between
positive and negative controls from dogs (IgG 4.3, 7.9, 8.8
and IgM 2.4, 3.0, 3.5) were obtained at dilutions of 1:80,
1:160, and 1:320, respectively (Figure 2B). Cutoff OD val-
ues of 0.288 for IgG and 0.219 for IgM were obtained with
serum samples from uninfected dogs in Mexico and
Germany. 
All serum samples were analyzed at a 1:100 dilution by
ELISA and IFC. The highest signal-to-noise ratio for
detection of antibody to trypomastigote surface antigens
by IFC was obtained with 5 × 105 parasites/reaction, which
was also reported in other studies (21,26). Positive and
negative control peaks were distinguishable: >90% of try-
pomastigotes incubated with negative sera (1:100 dilution)
had a fluorescence intensity (LFI) <10 and 50%–98% of
trypomastigotes incubated with positive sera (1:100 dilu-
tion) had an LFI of 102–103 (Figure 3).
Seroprevalence of T. cruzi–specific 
Antibodies in Humans 
At UTMB, we identified 9 seropositive persons (mean
seroprevalence 3.1%, range 0%–21%) from the villages of
Tejupilco municipality. The mean OD value, after subtract-
ing for background, for the seropositive population was
0.213, and the highest value was 0.419. IgG seropositivity
was similarly distributed among men and women (55% vs.
45%). All seropositive samples identified by ELISA were
positive for T. cruzi–specific IgG by IFC. Approximately
73% of the trypomastigotes (range 62%–91%) incubated
with positive serum samples had an LFI of 10 to 500.
Trypomastigotes (>98%) incubated with negative serum
samples had an LFI <10 (Figure 3). The results of ELISA
and IFC for detection of T. cruzi–specific antibodies
showed 100% agreement. T. cruzi–specific IgG was also
detected by ELISA, IIF, and IHAin a blind study at InDRE.
This study identified 7 seropositive human patients, of
whom 6 were positive by UTMB tests (Table 1). The max-
imal percentage seropositivity was identified in El Carmen
Ixtapan and El Puerto del Salitre, which are located at low
altitudes (Table 2). All 63 persons tested in La Comunidad
were seronegative (Table 2).
Our data showed that 16 (5.5%) of 293 persons in
Tejupilco were seropositive for IgM antibodies to T. cruzi
(Table 2). The prevalence of IgM antibodies was higher in
female than in male patients (64% vs. 36%). All serum
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Figure 2. Serum titration curves of enzyme-linked immunosorbent
assays comparing absorbance values for serial dilutions of pooled
positive (solid lines) and negative (dashed lines) control sera from
humans (A) and dogs (B). Absorbance values for immunoglobulin
G (IgG) and IgM antibodies to Trypanosoma cruzi are represented
by triangles and diamonds, respectively. samples positive by ELISA for IgM antibodies were also
positive by IFC (50%–93% of the parasites with an LFI of
102–103) (Figure 3). The overall prevalence of T.
cruzi–specific antibodies (IgG and IgM) in persons in
Tejupilco was 7.1% (21/293) (Table 2). 
Seroprevalence of T. cruzi–specific 
Antibodies in Dogs 
We used dog serum samples from Chiapas, where T.
cruzi infection and transmission were reportedly endemic
(7), as positive controls. These dogs had a seropositivity of
39.3% for IgG and 14.3% for IgM (Table 3 and Figure 4B).
Dogs in Tejupilco had antibodies to T. cruzi (IgG 15.8%,
IgM 11.4%, IgG and IgM 21.0%) (Table 3). A total of
6.1% of the dogs from Tejupilco were positive for both
IgG and IgM (Figure 4C), and no sex-related differences in
prevalence of parasite-specific antibodies were observed.
IgG seropositivity increased with age, with the highest
seroprevalence in dogs 3–6 years of age. All samples
seropositive by ELISAwere seropositive by IFC. Atotal of
57% to 94% of the parasites showed IgG-specific staining
(LFI 102–104), and 86%–98% showed IgM-specific stain-
ing (LFI 100 to 4 × 103) (Figure 3). Samples seropositive
for IgG were confirmed by IHA(data not shown). None of
the serum samples from dogs in northern villages (Apaxco,
Hueypoxtla, Jaltenco, and Nextlalpan) in the State of
Mexico or the German veterinary clinic (Figure 4A) had T.
cruzi–specific antibodies. This result demonstrated the
specificity and sensitivity of the assays used. Pairwise lin-
ear analysis showed a positive correlation of IgG seropos-
itivity in dogs and humans in study area (r2 = 0.955).
Parasite-specific antibodies (IgG 10%, IgM 15%, IgG and
IgM 17.5%) were detected in dogs from Toluca (Table 3
and Figure 4D), a region previously considered free of T.
cruzi infection.
Discussion
We detected T. cruzi–specific IgG and IgM in 7.1% of
persons and 21.0% of dogs in Tejupilco. In addition, we
observed an IgG and IgM seroprevalence of 17.5% in dogs
in Toluca, which was previously reported to be free of T.
cruzi infection. Epimastigote and trypomastigote antigens
and 5 different tests were used to determine IgG seroposi-
tivity in selected areas. Nine of 293 IgG-positive patients
were identified by trypomastigote-based tests, of whom 6
were also identified by >2 of the epimastigote-based tests
at InDRE. Low IgG seropositivity in the InDRE survey
might have occurred because epitopes shared by epi-
mastigote and trypomastigote forms are intracellular anti-
gens, whereas the IgG antibodies are specific for
trypomastigote surface antigens (27). Alternatively, low
seropositivity may be attributed to different parasite strains
used for serologic tests at the 2 institutes. Apositive corre-
lation between IgG seropositivity in humans and dogs (r2
= 0.955) implies that dogs help identify or monitor sero-
prevalence in these populations.
Serologic analysis has been reported to be limited in
acute infections with T. cruzi (23,24). With trypomastigote
antigens, we detected an IgM seroprevalence of 5.5% in
humans, thus demonstrating that a robust T. cruzi–specific
IgM response is mounted by humans. In addition, most of
the IgM-positive persons were IgG negative. These data,
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Figure 3. Detection of antibodies to Trypanosoma cruzi by
immunofluorescence flow cytometry. Fluorescein isothiocyanate
fluorescence intensities for T. cruzi–specific immunoglobulin G
(IgG) and IgM antibodies in human and dog serum samples are
shown. Background staining with normal serum, positive staining
with chronic serum, and representative staining with 2 of the test
serum samples are shown. along with the observation of high IgM seropositivity
(11.4%) in dogs from the same area, suggest the occur-
rence of acute T. cruzi infection in rural villages in the
State of Mexico. This view is supported by Wickner et al.,
who reported polymerase chain reaction–based detection
of T. cruzi in blood samples from patients with acute infec-
tion identified as IgM seropositive by ELISA (agreement
94%) (28).
Our study identified seropositive patients (7.1%) and
high seroprevalence (21.0%) in dogs from southern vil-
lages in the State of Mexico, which has a low altitude
(<1,700 m) and warm temperatures. Nearly all inhabitants
screened in the study had dogs that lived near their owners
in small quarters, and we observed a correlation between
seropositivity in dogs and humans in these communities. 
Previous reports showed infestation with T. barberi and
T. pallidipennis at low altitudes (<2,000 m) in all areas of
Mexico (4) and inside and around houses in the southern
part of the State of Mexico (12). Dogs provide frequent
blood meals for T. barberi and T.  pallidipennis and may
acquire T. cruzi infection by ingesting infected tri-
atomines. We surmise that the active transmission of T.
cruzi occurs in the southern part of the State of Mexico,
and the presence of T. cruzi in dogs and insect vectors can
help determine the prevalence of T. cruzi infection in
humans. Thus, low altitudes and warm temperatures may
sustain vectorial activity and T. cruzi transmission in
southern Mexico. Several observations support our
hypothesis. First, dogs maintain parasitemia long after
infection (29) and are the preferred source of blood meals
for Triatoma infestans (30). Second, the prevalence rate of
infective T. infestans in a household increases with the
number of infected dogs in the vicinity (13). In accordance
with the increase in infected insects, the seroprevalence of
infected adults doubled in households with 1 to 2 infected
dogs (14). Third, T. cruzi–specific antibodies have been
identified in humans (4%) and dogs (10%) in rural villages
of Puebla, Mexico, where active vectorial transmission,
shown by a high dispersion area index (55%) and coloniza-
tion index (40%), was also noted (17).
We observed a high seroprevalence of IgG and IgM
antibodies (17.5%) in dogs from Toluca. Additional studies
would determine whether changes in behavior and localiza-
tion of triatomines at higher altitudes may lead to T. cruzi
infection in dogs in Toluca. Alternatively, a high rate of
migration from endemic to nonendemic zones exists in
Mexico. At institutional blood banks, ≈40% of donors
reported to be permanent residents of Mexico City were
born in other states of Mexico (C. Guzman-Bracho, unpub.
data). These immigrants bring their domestic animals with
them, and thus may inadvertently contribute to the spread
of T. cruzi infection. Our detection of T. cruzi in dogs from
Toluca suggests that this city and others in Mexico located
at high altitudes may not be free of T. cruzi infection. 
RESEARCH
628 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 4, April 2006The seroprevalence of 21.0% (IgG and IgM) in dogs
and the observed vectorial activity in these areas suggest
that dogs may be domestic reservoir hosts and help main-
tain human transmission of T. cruzi. Our observations
emphasize the importance of active epidemiologic surveil-
lance programs throughout Mexico and implementation of
sound vector control strategies in disease-endemic areas.
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measles
Highly contagious disease caused by a virus of the genus Morbillivirus, marked by an eruption of
distinct, red, circular spots. From the Middle Dutch masel, “blemish.” References to the disease date
back to at least 700 AD, but the first recorded scientific description of measles was in the 10th
century AD by the Persian physician Ibn Razi, who described it as “more dreaded than smallpox.”
Prior to 1963, when the first measles vaccine was licensed, 3–4 million cases and 450 deaths
occurred in the United States every year. Measles remains a primary cause of death in developing
nations, where vitamin A deficiency is common. According to the World Health Organization,
measles is the leading cause of vaccine-preventable death in children; it is responsible for ≈850,000
deaths each year.
Sources: Merriam-Webster's collegiate dictionary. 11th ed. Springfield (MA): Merriam-Webster Incorporated; 2003; Centers
for Disease Control and Prevention. Measles history. Available from http://www.cdc.gov/nip/diseases/measles/history.htm;
and World Health Organization. Measles mortality reduction and regional elimination. Available from http://www.who.int/vac-
cines-documents/DocsPDF01/www573.pdf
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